Evidence map›Paper›PMID 28296559›Full record

ArticleCell cycle (Georgetown, Tex.)2017

The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago.

Takashi Murakami, Tasuku Kiyuna, Kei Kawaguchi, Kentaro Igarashi, Arun S Singh, Yukihiko Hiroshima, Yong Zhang, Ming Zhao, Kentaro Miyake, Scott D Nelson and 10 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Tumor-targetingHeliyon · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Takashi Murakamia AntiCancer, Inc. , San Diego , CA , USA.
Tasuku Kiyunaa AntiCancer, Inc. , San Diego , CA , USA.
Kei Kawaguchia AntiCancer, Inc. , San Diego , CA , USA.
Kentaro Igarashia AntiCancer, Inc. , San Diego , CA , USA.
Arun S Singhd Division of Hematology-Oncology , University of California , Los Angeles , CA , USA.
Yukihiko Hiroshimac Department of Gastroenterological Surgery , Graduate School of Medicine, Yokohama City University , Yokohama , Japan.
Yong Zhanga AntiCancer, Inc. , San Diego , CA , USA.
Ming Zhaoa AntiCancer, Inc. , San Diego , CA , USA.
Kentaro Miyakea AntiCancer, Inc. , San Diego , CA , USA.ORCID http://orcid.org/0000-0002-4680-4317
Scott D Nelsone Department of Pathology , University of California , Los Angeles , CA , USA.
Sarah M Drye Department of Pathology , University of California , Los Angeles , CA , USA.
Yunfeng Lie Department of Pathology , University of California , Los Angeles , CA , USA.
Jonathan C DeLongb Department of Surgery , University of California , San Diego , CA , USA.
Thinzar M Lwinb Department of Surgery , University of California , San Diego , CA , USA.
Takashi Chishimac Department of Gastroenterological Surgery , Graduate School of Medicine, Yokohama City University , Yokohama , Japan.
Kuniya Tanakac Department of Gastroenterological Surgery , Graduate School of Medicine, Yokohama City University , Yokohama , Japan.
Michael Bouvetb Department of Surgery , University of California , San Diego , CA , USA.
Itaru Endoc Department of Gastroenterological Surgery , Graduate School of Medicine, Yokohama City University , Yokohama , Japan.ORCID http://orcid.org/0000-0001-5520-8114
Fritz C Eilberf Division of Surgical Oncology , University of California , Los Angeles , CA , USA.ORCID http://orcid.org/0000-0003-3336-9333
Robert M Hoffmana AntiCancer, Inc. , San Diego , CA , USA.
University of California San Diego · USAntiCancer (United States) · USUniversity of California, Los Angeles · USYokohama City University · JP

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

William B. Coley developed bacterial therapy of cancer more than 100 years ago and had clinical success. James Ewing, a very famous cancer pathologist for whom the Ewing sarcoma is named, was Coley's boss at Memorial Hospital in New York and terminated Coley's bacterial therapy of cancer. A tumor from a patient with soft-tissue Ewing's sarcoma, who failed doxorubicin (DOX) therapy, was previously implanted in nude mice to establish a patient-derived orthotopic xenograft (PDOX) model. In the present study, the Ewing's sarcoma PDOX was treated with tumor-targeting S. typhimurium A1-R expressing green fluorescent (GFP), alone and in combination with DOX. S. typhimurium A1-R-GFP was detected in the tumors after intratumor (i.t.) or intravenous (i.v.) injection. The combination of S. typhimurium A1-R and DOX significantly reduced tumor weight (37.8 ± 15.6 mg) compared to the untreated control (73.8 ± 10.1 mg, P < 0.01). S. typhimurium A1-R monotherapy-treated tumors tended to be smaller (50.9 ± 17.8 mg, P = 0.051). DOX monotherapy did not show efficacy (66.3 ± 26.4 mg, P = 0.82), as was the case with the patient. The PDOX model faithfully replicated the DOX resistance the Ewing's sarcoma had in the patient. S. typhimurium A1-R converted the Ewing's sarcoma from DOX resistant to sensitive. One can only wonder how bacterial therapy and immunotherapy of cancer would have developed over the past 80 years if Ewing did not stop Coley.

Indexed as

Xenograft Model Antitumor AssaysAnimalsDoxorubicinFemaleGreen Fluorescent ProteinsHumansMiceMice, NudeMiddle AgedSalmonella typhimuriumSarcoma, EwingDoxorubicinGreen Fluorescent Proteinsbacterial therapy of cancerEwing's sarcomapatient-derived orthotopic xenograftPDOXSalmonella typhimurium A1-R

Identifiers

PMID28296559
PMCPMC5499836
OpenAlexW2612864403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.